- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00064701
Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients
A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (Tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (Cyclosporine)/MMF in de Novo Kidney Transplant Recipients
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
This was a 3 arm randomized, open-label, comparative, multi-center study in de novo kidney transplant recipients at 60 centers in the U.S., Canada and Brazil.
The study consisted of a 1-year post-transplant efficacy and safety study with a clinical continuation phase of a minimum of 2 years or until commercial availability of tacrolimus modified release, unless the Data Safety Monitoring Board or sponsor specified otherwise.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Porto Alegre, Brasilien, 90240-520
-
Rio de Janeiro, Brasilien, 21041-003
-
Sao Paulo, Brasilien, 04038-002
-
Sao Paulo, Brasilien, 04013-043
-
Sao Paulo, Brasilien, 05465-040
-
-
-
-
Alberta
-
Edmonton, Alberta, Kanada
-
-
British Columbia
-
Vancouver, British Columbia, Kanada
-
-
Ontario
-
Toronto, Ontario, Kanada
-
-
Quebec
-
Montreal, Quebec, Kanada
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35294
-
Mobile, Alabama, Vereinigte Staaten, 36617
-
-
California
-
Loma Linda, California, Vereinigte Staaten, 92354
-
Los Angeles, California, Vereinigte Staaten, 90033
-
Los Angeles, California, Vereinigte Staaten, 90057
-
Los Angeles, California, Vereinigte Staaten, 90058
-
Los Angeles, California, Vereinigte Staaten, 90095-7306
-
Palo Alto, California, Vereinigte Staaten, 94304
-
San Diego, California, Vereinigte Staaten, 92103
-
San Diego, California, Vereinigte Staaten, 92123
-
San Francisco, California, Vereinigte Staaten, 94115
-
-
Colorado
-
Denver, Colorado, Vereinigte Staaten, 80262
-
-
District of Columbia
-
Washington, District of Columbia, Vereinigte Staaten, 20010
-
-
Florida
-
Gainesville, Florida, Vereinigte Staaten, 32610-0224
-
Jacksonville, Florida, Vereinigte Staaten, 32216
-
-
Georgia
-
Augusta, Georgia, Vereinigte Staaten, 30912
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60637
-
Chicago, Illinois, Vereinigte Staaten, 60612
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40536
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
-
New Orleans, Louisiana, Vereinigte Staaten, 70121
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02214
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109-0364
-
Detroit, Michigan, Vereinigte Staaten, 48202
-
-
New Jersey
-
Livingston, New Jersey, Vereinigte Staaten, 07039
-
New Brunswick, New Jersey, Vereinigte Staaten, 08901
-
-
New York
-
Albany, New York, Vereinigte Staaten, 12208
-
Buffalo, New York, Vereinigte Staaten, 14203
-
New York, New York, Vereinigte Staaten, 10029
-
Valhalla, New York, Vereinigte Staaten, 10595
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599-7211
-
Durham, North Carolina, Vereinigte Staaten, 27710
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45267
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97210
-
Portland, Oregon, Vereinigte Staaten, 97239-2940
-
-
Pennsylvania
-
Harrisburg, Pennsylvania, Vereinigte Staaten, 17104
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37212-4750
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75246
-
Dallas, Texas, Vereinigte Staaten, 75235
-
Houston, Texas, Vereinigte Staaten, 77030
-
San Antonio, Texas, Vereinigte Staaten, 78229-3900
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84132
-
-
Virginia
-
Fairfax, Virginia, Vereinigte Staaten, 22031
-
-
Wisconsin
-
Madison, Wisconsin, Vereinigte Staaten, 53792-7375
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Recipient of a primary or retransplanted non-human leukocyte antigen (HLA)-identical living or non-HLA-identical cadaveric kidney transplant
- Age greater or equal to 12 years
Exclusion Criteria:
- Recipient or donor is known seropositive for human immunodeficiency virus (HIV)
- Has current malignancy or history of malignancy
- Has significant liver disease
- Has uncontrolled concomitant infection or any other unstable medical condition
- Is receiving everolimus or enteric coated mycophenolic acid at any time during the study
- Received kidney with a cold ischemia time of equal or more than 36 hours
- Received kidney transplant from a cadaveric donor equal or more than 60 years of age
- Received intravenous immunoglobulin (IVIG) therapy prior to randomization
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Tacrolimus
Participants received a first dose of tacrolimus between 0.075 and 0.10 mg/kg twice daily, orally prior to or within 48 hours of the completion of the transplant procedure, and subsequently as twice daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events.
Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
|
The target range for whole blood tacrolimus trough concentrations was the recommended trough concentration range for Prograf: 7 to 16 ng/mL for days 0 through 90 and 5 to 15 ng/mL thereafter.
Andere Namen:
Oral
Andere Namen:
|
Aktiver Komparator: Tacrolimus Modified Release
Participants received a first dose of tacrolimus modified release between 0.15 and 0.20 mg/kg/day, given as a single oral dose in the morning, prior to or within 48 hours following the completion of the transplant procedure, and subsequently as once daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events.
Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
|
Oral
Andere Namen:
The target range for whole blood tacrolimus trough concentrations was 7 to 16 ng/mL for days 0 through 90, and 5 to 15 ng/mL thereafter.
Andere Namen:
|
Aktiver Komparator: Cyclosporine
Participants received a first dose of cyclosporine between 4 to 5 mg/kg orally prior to or within 48 hours following the completion of the transplant procedure and subsequently as twice daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events.
Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
|
Oral
Andere Namen:
The target range for whole blood cyclosporine trough concentrations was 125 to 400 ng/mL for days 0 through 90, and 100 to 300 ng/mL thereafter.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Percentage of Participants With Efficacy Failure
Zeitfenster: one year
|
Efficacy failure is defined as any participant who died, experienced a graft failure (permanent return to dialysis [> 30 days] or retransplant), had a biopsy-confirmed (Banff Grade ≥ I) acute rejection (BCAR), or was lost to follow-up. Biopsies were graded according to the 1997 Banff criteria: Borderline: No intimal arteritis present but foci of mild tubulitis; Grade I: Significant interstitial infiltration and foci of moderate to severe tubulitis; Grade II: Mild to severe intimal arteritis Grade III: Transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic infiltrate in vessel. |
one year
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Patient Survival at One Year
Zeitfenster: One year
|
Patient survival is defined as any participant who is known to be alive one year after the skin closure date.
Participants who died or whose outcome was unknown at one year were considered to be non-survivors.
|
One year
|
Graft Survival at One Year
Zeitfenster: One year
|
Graft survival defined as any participant who did not meet the criteria for graft loss, where graft loss is defined as any re-transplant, permanent return to dialysis (> 30 days), patient death, or participant whose outcome at one year was unknown. Participants were only counted once regardless of how many criteria were met. |
One year
|
Percentage of Participants With Biopsy Confirmed Acute Rejection at 6 and 12 Months
Zeitfenster: Six months and 12 months
|
Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 1997 Banff criteria: Borderline: No intimal arteritis present but foci of mild tubulitis; Grade I: Significant interstitial infiltration and foci of moderate to severe tubulitis; Grade II: Mild to severe intimal arteritis Grade III: Transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic infiltrate in vessel. Acute rejection is defined as a grade ≥ I. |
Six months and 12 months
|
Time to First Biopsy-confirmed Acute Rejection Episode
Zeitfenster: one year
|
Time to first biopsy-confirmed acute rejection episode defined as the number of days from skin closure (Day 0) to the date of biopsy. Rejection episodes were confirmed by biopsy by the clinical site pathologist and graded according to the 1997 Banff criteria: Borderline: No intimal arteritis present but foci of mild tubulitis; Grade I: Significant interstitial infiltration and foci of moderate to severe tubulitis; Grade II: Mild to severe intimal arteritis Grade III: Transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic infiltrate in vessel. Acute rejection is defined as a grade ≥ I. |
one year
|
Number of Participants Requiring Anti-lymphocyte Antibody Therapy for Treatment of Rejection
Zeitfenster: one year
|
Rejection episodes were confirmed by biopsy by the clinical site pathologist. Participants with histologically-proven Banff Grade II or III rejection or participants with steroid-resistant rejection were treated with anti-lymphocyte antibody treatment according to institutional practice. Biopsies were graded according to the 1997 Banff criteria: Borderline: No intimal arteritis present but foci of mild tubulitis; Grade I: Significant interstitial infiltration and foci of moderate to severe tubulitis; Grade II: Mild to severe intimal arteritis Grade III: Transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic infiltrate in vessel. |
one year
|
Severity of Acute Rejection
Zeitfenster: one year
|
Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 1997 Banff criteria: Borderline: No intimal arteritis present but foci of mild tubulitis; Grade IA: Significant interstitial infiltration and foci of moderate tubulitis; Grade IB: Significant interstitial infiltration and foci of severe tubulitis; Grade IIA: Mild to moderate intimal arteritis in at least 1 arterial cross section Grade IIB: Severe intimal arteritis comprising >25% of the luminal area lost in at least 1 arterial cross section; Grade III: Transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic infiltrate in vessel. |
one year
|
Number of Participants Experiencing Multiple Rejection Episodes
Zeitfenster: one year
|
This analysis includes rejection episodes that were either confirmed by biopsy by the clinical site pathologist or were clinically treated.
|
one year
|
Number of Participants With Clinically Treated Acute Rejection Episodes
Zeitfenster: one year
|
A clinically treated acute rejection episode was any biopsy-confirmed or suspected rejection episode that was treated with immunosuppressive therapy.
|
one year
|
Number of Participants With Treatment Failure
Zeitfenster: one year
|
Treatment failure was defined as the discontinuation of randomized study drug for any reason.
Participants who met the definition of treatment failure were to be followed throughout the 12-month treatment period.
|
one year
|
Number of Participants Who Crossed Over Due to Treatment Failure
Zeitfenster: one year
|
Participants were allowed to cross over to an alternative primary immunosuppressive regimen (either to the tacrolimus or cyclosporine treatment arms) to address an adverse event which led to randomized study drug discontinuation or in the case of severe or refractory rejection.
Crossover to the modified release tacrolimus treatment arm was not permitted.
|
one year
|
Change From Month 1 in Serum Creatinine at Month 6 and Month 12
Zeitfenster: Month 1, Month 6, and Month 12
|
Renal function was assessed by the change from Month 1 in serum creatinine six months and 12 months after transplant.
|
Month 1, Month 6, and Month 12
|
Change From Month 1 in Creatinine Clearance at Month 6 and Month 12
Zeitfenster: Month 1, Month 6, and Month 12
|
Renal function was assessed by creatinine clearance, calculated using the Cockcroft-Gault formula.
|
Month 1, Month 6, and Month 12
|
Kaplan-Meier Estimate of Patient Survival at the End of the Study
Zeitfenster: End of study (maximum time on study was 1,941 days).
|
Patient survival was defined as any participant who was alive at the end of the study.
Patient survival was censored at the time of last follow-up contact.
|
End of study (maximum time on study was 1,941 days).
|
Kaplan-Meier Estimate of Graft Survival at the End of the Study
Zeitfenster: End of study (maximum time on study was 1,941 days).
|
Graft survival was defined as any participant who did not meet the definition of graft loss, where graft loss was any retransplant or the permanent return to dialysis (more than 30 days) or patient death. Graft survival was censored at the time of last follow-up contact. |
End of study (maximum time on study was 1,941 days).
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Enzym-Inhibitoren
- Antirheumatika
- Antineoplastische Mittel
- Immunsuppressive Mittel
- Immunologische Faktoren
- Dermatologische Wirkstoffe
- Antibakterielle Mittel
- Antibiotika, antineoplastische
- Antimykotika
- Antituberkulöse Mittel
- Antibiotika, Antituberkulose
- Calcineurin-Inhibitoren
- Tacrolimus
- Mycophenolsäure
- Cyclosporin
- Cyclosporine
Andere Studien-ID-Nummern
- 02-0-158
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Nierentransplantation
-
University Health Network, TorontoNoch keine RekrutierungSolide Organtransplantation | Leber-Transplantation | Nierentransplantation | Herz Transplantation
-
Washington University School of MedicineNational Marrow Donor Program; Predictive BioDiagnostics, LLCAbgeschlossenTransplantation hämatopoetischer Stammzellen | Stammzelltransplantation, hämatopoetisch | Transplantation, hämatopoetische StammzelleVereinigte Staaten
-
Assistance Publique - Hôpitaux de ParisRekrutierungTransplantation | Haploidentische TransplantationFrankreich
-
Icahn School of Medicine at Mount SinaiThe Hospital for Sick Children; Baylor College of Medicine; Children's Hospital... und andere MitarbeiterAktiv, nicht rekrutierendVerbesserung der Medikamentenadhärenz bei Jugendlichen, die eine Lebertransplantation hatten (iMALT)TransplantationVereinigte Staaten, Kanada
-
CareDxBeendetTransplantationVereinigte Staaten
-
University of California, San FranciscoBristol-Myers SquibbZurückgezogenTransplantation
-
Southern Medical University, ChinaThird Affiliated Hospital, Sun Yat-Sen University; 181 Central Hospital of the...Abgeschlossen
-
Astellas Pharma IncAbgeschlossenTransplantationFrankreich, Italien, Polen, Deutschland, Spanien, Belgien, Schweiz, Finnland, Tschechische Republik, Ungarn, Österreich, Dänemark, Schweden
-
Astellas Pharma IncAbgeschlossenTransplantationFrankreich, Spanien, Deutschland, Vereinigtes Königreich, Irland, Polen
Klinische Studien zur Tacrolimus
-
Novartis PharmaceuticalsAbgeschlossenEmpfänger einer LebertransplantationBelgien, Spanien, Deutschland, Italien, Australien, Vereinigte Staaten, Niederlande, Irland, Schweden, Brasilien, Kolumbien, Frankreich, Russische Föderation, Argentinien, Tschechien, Vereinigtes Königreich
-
Novartis PharmaceuticalsAbgeschlossenLebertransplantationVereinigte Staaten, Belgien, Kolumbien, Spanien, Deutschland, Italien, Australien, Israel, Frankreich, Ungarn, Niederlande, Argentinien, Kanada, Irland, Schweden, Brasilien, Vereinigtes Königreich, Russische Föderation, Tschechische...
-
Heleen GrootjansChiesi Farmaceutici S.p.A.RekrutierungLungentransplantation; KomplikationenNiederlande
-
Taro Pharmaceuticals USAAbgeschlossen
-
Astellas Pharma IncAstellas Pharma Korea, Inc.AbgeschlossenLebertransplantationKorea, Republik von
-
University of British ColumbiaPaladin Labs Inc.RekrutierungLebertransplantation | Neurotoxizität | Tremor | Tacrolimus | ImmunsuppressionKanada
-
Technical University of MunichAbgeschlossen
-
Limerick BioPharmaAbgeschlossen
-
The Eye Center and The Eye Foundation for Research...UnbekanntKeratokonjunktivitis im FrühlingSaudi-Arabien
-
Panacea Biotec LtdAbgeschlossenGesunde FreiwilligeIndien